Inactive Instrument

Cubist Pharmaceuticals Inc Share Price

Stocks

End-of-day quote Nasdaq
- ^USD	-

10/14/10	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/14/09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/14/10	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/14/09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/14/09	Merck : to take on superbugs with Cubist Pharma buy	RE
09/14/09	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/14/09	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
08/14/08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/14/06	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/13/21	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

13/15/13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/14/20	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
16/14/16	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
13/14/13	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
12/14/12	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

21/14/21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
21/14/21	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
09/14/09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
08/14/08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
08/14/08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	-1.69%	+2.56%	+39.87%	+1.75%	8.25TCr
MODERNA, INC.	-23.55%	+109.46%	+395.80%	+31.19%	5.32TCr
CSL LIMITED	-1.69%	+23.30%	-25.53%	-36.93%	5.84TCr
SAMSUNG BIOLOGICS CO.,LTD.	+1.94%	+0.64%	+0.46%	+32.78%	5.22TCr
UCB	-0.14%	+2.50%	+9.35%	+166.99%	4.85TCr
BIOGEN INC.	-3.25%	+1.76%	+54.22%	-17.92%	3.17TCr
INCYTE CORPORATION	-0.97%	+5.56%	+47.59%	+98.66%	2.58TCr
INNOVENT BIOLOGICS, INC.	+1.19%	+9.17%	+3.12%	+228.73%	2.25TCr
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	+4.36%	+60.70%	+123.98%	1.69TCr
Average	-0.89%	+17.01%	+65.06%	+69.91%	4.35TCr
Weighted average by Cap.	-1.06%	+20.07%	+69.91%	+47.67%

Employees

Sector